JP2021530504A5 - - Google Patents
Info
- Publication number
- JP2021530504A5 JP2021530504A5 JP2021501041A JP2021501041A JP2021530504A5 JP 2021530504 A5 JP2021530504 A5 JP 2021530504A5 JP 2021501041 A JP2021501041 A JP 2021501041A JP 2021501041 A JP2021501041 A JP 2021501041A JP 2021530504 A5 JP2021530504 A5 JP 2021530504A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- cancer
- peg
- dosage form
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699963P | 2018-07-18 | 2018-07-18 | |
| US62/699,963 | 2018-07-18 | ||
| PCT/US2019/042382 WO2020018778A1 (en) | 2018-07-18 | 2019-07-18 | Polymeric nanoparticles comprising salinomycin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530504A JP2021530504A (ja) | 2021-11-11 |
| JP2021530504A5 true JP2021530504A5 (https=) | 2022-07-26 |
| JPWO2020018778A5 JPWO2020018778A5 (https=) | 2022-07-26 |
Family
ID=67704555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021501041A Pending JP2021530504A (ja) | 2018-07-18 | 2019-07-18 | サリノマイシンを含む高分子ナノ粒子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200046648A1 (https=) |
| EP (1) | EP3823589A1 (https=) |
| JP (1) | JP2021530504A (https=) |
| KR (1) | KR20210053881A (https=) |
| CN (1) | CN113164375A (https=) |
| AU (1) | AU2019307629A1 (https=) |
| CA (1) | CA3105731A1 (https=) |
| WO (1) | WO2020018778A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3186633A1 (en) * | 2020-06-30 | 2022-01-06 | Hillstream Biopharma Inc. | Nanoparticles and methods of manufacture thereof |
| WO2022251844A1 (en) * | 2021-05-25 | 2022-12-01 | Hillstream Biopharma, Inc. | Polymeric nanoparticles comprising chemotherapeutic compounds and related methods |
| CN116570584B (zh) * | 2023-05-08 | 2025-02-18 | 广州白云山医药集团股份有限公司白云山制药总厂 | 盐霉素在制备降尿酸和/或治疗高尿酸血症的药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060165987A1 (en) | 2002-04-05 | 2006-07-27 | Patrice Hildgen | Stealthy polymeric biodegradable nanospheres and uses thereof |
| AU2006278718B2 (en) | 2005-08-03 | 2010-10-07 | Secura Bio Inc. | Use of HDAC inhibitors for the treatment of myeloma |
| KR101445405B1 (ko) | 2006-07-28 | 2014-09-26 | 가부시키가이샤 브리지스톤 | 상간 영역을 갖는 중합체성 코어-쉘 나노입자 |
| US20080081075A1 (en) | 2006-10-02 | 2008-04-03 | National Tsing Hua University | Multifunctional mixed micelle of graft and block copolymers and preparation thereof |
| US9149426B2 (en) | 2012-02-15 | 2015-10-06 | University Of Tennessee Research Foundation | Nanoparticle composition and methods to make and use the same |
| EP3778696A1 (en) | 2012-04-23 | 2021-02-17 | NanoProteagen Ltd. | Polymeric nanoparticles and a process of preparation thereof |
| WO2018049155A1 (en) * | 2016-09-08 | 2018-03-15 | Dana-Farber Cancer Institute, Inc. | Compositions comprising polymeric nanoparticles and mcl-1 antagonists |
| MY210233A (en) * | 2017-10-11 | 2025-09-04 | Illustris Pharmaceuticals Inc | Methods and compositions for topical delivery |
| WO2019104001A1 (en) * | 2017-11-22 | 2019-05-31 | Hillstream Biopharma Inc. | Polymeric nanoparticles comprising bortezomib |
-
2019
- 2019-07-18 CN CN201980047686.0A patent/CN113164375A/zh active Pending
- 2019-07-18 EP EP19756447.9A patent/EP3823589A1/en not_active Withdrawn
- 2019-07-18 CA CA3105731A patent/CA3105731A1/en active Pending
- 2019-07-18 AU AU2019307629A patent/AU2019307629A1/en not_active Abandoned
- 2019-07-18 WO PCT/US2019/042382 patent/WO2020018778A1/en not_active Ceased
- 2019-07-18 KR KR1020217004716A patent/KR20210053881A/ko not_active Ceased
- 2019-07-18 JP JP2021501041A patent/JP2021530504A/ja active Pending
- 2019-07-18 US US16/515,405 patent/US20200046648A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yamaguchi et al. | Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer | |
| US10849899B2 (en) | Combination therapy comprising Varlitinib and an anticancer agent | |
| Wu et al. | Nanoparticle-based combination therapy for ovarian cancer | |
| US11648211B2 (en) | Nanoencapsulated combination drug formulations | |
| JP2016513657A5 (https=) | ||
| JP2017171685A5 (https=) | ||
| JP2006524246A5 (https=) | ||
| JP2021530504A5 (https=) | ||
| JP2019521087A5 (https=) | ||
| JP2009539769A5 (https=) | ||
| JP2006515883A5 (https=) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2012521435A5 (https=) | ||
| Grau et al. | Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. | |
| Gisselbrecht et al. | Fluorouracil (F), adriamycin (A), and cisplatin (P)(FAP): combination chemotherapy of advanced esophageal carcinoma | |
| JP2018536655A5 (https=) | ||
| Jiang et al. | Research progress of carrier-free antitumor nanoparticles based on phytochemicals | |
| Yadav et al. | Innovative nanoparticulate strategies in colon cancer treatment: a paradigm shift | |
| Hofstra et al. | Intraperitoneal chemotherapy in ovarian cancer | |
| JP2008540364A5 (https=) | ||
| WO2017200492A1 (en) | Method of treating cancer | |
| JP2021517886A5 (https=) | ||
| Hu et al. | Current status of CPT and its analogues in the treatment of malignancies | |
| JPWO2020018778A5 (https=) | ||
| Ogawa | A recent overview of chemotherapy for advanced stomach cancer in Japan |